Breaking News

Achilles Therapeutics Expands UK and U.S. Manufacturing Capabilities

Expansion will supply clinical grade cNeT for ongoing Phase I/IIa clinical trials and support future development.

Author Image

By: Charlie Sternberg

Associate Editor

Achilles Therapeutics plc, a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, is expanding its clinical manufacturing in the United Kingdom and the United States.   Achilles’ manufacturing facility at the Cell & Gene Therapy Catapult (Catapult) in Stevenage, UK, has received a manufacturing license from the Medicines and Healthcare products Regulatory Agency (MHRA) and, separately, the company has entered into a partnership agreement for...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters